Literature DB >> 1846706

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.

D P Bottaro1, J S Rubin, D L Faletto, A M Chan, T E Kmiecik, G F Vande Woude, S A Aaronson.   

Abstract

Hepatocyte growth factor (HGF) is a plasminogen-like protein thought to be a humoral mediator of liver regeneration. A 145-kilodalton tyrosyl phosphoprotein observed in rapid response to HGF treatment of intact target cells was identified by immunoblot analysis as the beta subunit of the c-met proto-oncogene product, a membrane-spanning tyrosine kinase. Covalent cross-linking of 125I-labeled ligand to cellular proteins of appropriate size that were recognized by antibodies to c-met directly established the c-met product as the cell-surface receptor for HGF.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1846706     DOI: 10.1126/science.1846706

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  552 in total

Review 1.  Roles of hepatocyte growth factor/scatter factor and transforming growth factor-beta1 in mammary gland ductal morphogenesis.

Authors:  J V Soriano; M S Pepper; L Orci; R Montesano
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-04       Impact factor: 2.673

Review 2.  HGF/SF in mammary epithelial growth and morphogenesis: in vitro and in vivo models.

Authors:  T Kamalati; B Niranjan; J Yant; L Buluwela
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-01       Impact factor: 2.673

3.  The multisubstrate docking site of the MET receptor is dispensable for MET-mediated RAS signaling and cell scattering.

Authors:  D Tulasne; R Paumelle; K M Weidner; B Vandenbunder; V Fafeur
Journal:  Mol Biol Cell       Date:  1999-03       Impact factor: 4.138

Review 4.  Dysregulation of Met receptor tyrosine kinase activity in invasive tumors.

Authors:  Alla Danilkovitch-Miagkova; Berton Zbar
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

Review 5.  Invasive growth: from development to metastasis.

Authors:  Paolo M Comoglio; Livio Trusolino
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

6.  Hepatocyte growth factor activates phosphoinositide 3-kinase C2 beta in renal brush-border plasma membranes.

Authors:  Vladiana Crljen; Stefano Volinia; Hrvoje Banfic
Journal:  Biochem J       Date:  2002-08-01       Impact factor: 3.857

7.  The processing and utilization of hepatocyte growth factor/scatter factor following partial hepatectomy in the rat.

Authors:  P Pediaditakis; J C Lopez-Talavera; B Petersen; S P Monga; G K Michalopoulos
Journal:  Hepatology       Date:  2001-10       Impact factor: 17.425

8.  Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer.

Authors:  Shuying Liu; Shunqiang Li; Bailiang Wang; Wenbin Liu; Mihai Gagea; Huiqin Chen; Joohyuk Sohn; Napa Parinyanitikul; Tina Primeau; Kim-Anh Do; George F Vande Woude; John Mendelsohn; Naoto T Ueno; Gordon B Mills; Debu Tripathy; Ana M Gonzalez-Angulo
Journal:  Mol Cancer Ther       Date:  2018-12-05       Impact factor: 6.261

Review 9.  Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future.

Authors:  Ishwaria M Subbiah; Ana Maria Gonzalez-Angulo
Journal:  Curr Treat Options Oncol       Date:  2014-03

10.  Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.

Authors:  Cleo E Rolle; Rajani Kanteti; Mosmi Surati; Suvobroto Nandi; Immanuel Dhanasingh; Soheil Yala; Maria Tretiakova; Qudsia Arif; Todd Hembrough; Toni M Brand; Deric L Wheeler; Aliya N Husain; Everett E Vokes; Ajit Bharti; Ravi Salgia
Journal:  Mol Cancer Ther       Date:  2013-12-10       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.